Buy Gleevec

Gleevec

Gleevec: What Is It?

Gleevec is a brand name for the oncology medication whose active ingredient is imatinib. Imatinib is a targeted cancer therapy that belongs to the class of tyrosine-kinase inhibitors. In Hong Kong, Gleevec is available only by prescription and is supplied as a pill in strengths of 100 mg and 400 mg. It is manufactured by Novartis and is regulated by the Hong Kong Department of Health under the Pharmacy and Poisons Ordinance.

How Gleevec Works in the Body

Imatinib works by blocking specific enzymes called tyrosine kinases that signal cancer cells to grow and divide. The drug binds to the ATP-binding site of these enzymes, preventing them from activating downstream pathways that drive tumor proliferation. By inhibiting the activity of the BCR-ABL fusion protein, as well as the c-KIT and PDGFR receptors, Gleevec reduces the uncontrolled growth of certain cancer cells. The effect usually begins within a few days, with maximal tumor response observed over several weeks to months. Imatinib is taken orally, absorbed into the bloodstream, and metabolized primarily by the liver enzyme CYP3A4.

Conditions Treated with Gleevec

Gleevec is approved for several oncology indications, including:

• Chronic myeloid leukemia (CML) in chronic, accelerated, or blast phases
• Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
• Gastrointestinal stromal tumor (GIST) that expresses the c-KIT mutation
• Other rare tumors such as malignant hypereosinophilic syndrome and myelodysplastic/myeloproliferative neoplasms when they have a relevant tyrosine-kinase abnormality

These approvals are based on regulatory assessments by agencies such as the U.S. FDA, European Medicines Agency (EMA), and the Hong Kong Department of Health.

Patient Suitability and Contraindications

Who Should Use Gleevec?

• Adults who have been diagnosed with one of the approved malignancies and for whom a healthcare professional has determined that imatinib is appropriate.
• Patients with adequate liver and kidney function, unless dose adjustments are recommended.

Absolute Contraindications

• Known hypersensitivity to imatinib or any of the tablet’s excipients.
• Pregnancy (imatinib is classified as a Category D medication in Hong Kong; it may cause fetal harm). Women of child-bearing potential should use effective contraception.

Relative Contraindications

• Severe liver impairment (bilirubin > 3 × upper limit of normal) - dose reduction may be required.
• Moderate to severe renal impairment (creatinine clearance < 30 mL/min) - consider a lower dose.
• Concurrent use of strong CYP3A4 inducers (e.g., rifampin, carbamazepine) which may lower imatinib exposure.

Special Populations

• Pregnancy & Lactation: Gleevec should be avoided; discuss alternative therapies with an oncologist.
• Elderly patients: Start at the standard dose but monitor closely for tolerability and organ function.
• Pediatric use: Not covered in this article; dosing in children follows separate guidelines.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Nausea or vomiting
• Diarrhea
• Edema (especially around the ankles)
• Fatigue or weakness
• Muscle cramps or pain
• Skin rash or mild itching

These effects are frequently reported and are usually manageable with supportive care or dose adjustments.

Serious Adverse Events

• Hematologic toxicity (low blood counts such as neutropenia, anemia, or thrombocytopenia) which can increase infection risk.
• Hepatotoxicity (elevated liver enzymes, jaundice) - requires laboratory monitoring.
• Cardiotoxicity (rare cases of congestive heart failure or reduced left-ventricular ejection fraction).
• Severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis.

Any sudden or severe symptom-especially fever, unusual bleeding, shortness of breath, or yellowing of the eyes-should prompt immediate medical attention.

Drug Interactions

• Major interactions: Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase imatinib plasma levels, raising the risk of toxicity. Strong CYP3A4 inducers (e.g., phenytoin, St. John’s wort) can reduce drug exposure and compromise efficacy.
• Moderate interactions: Acid-reducing agents (e.g., proton-pump inhibitors, antacids) may slightly lower imatinib absorption; spacing the doses by at least 2 hours is advisable.
• Herbal supplements: Caution with black cohosh, ginkgo, or other products that may affect platelet function or liver enzymes.

Patients should disclose all prescription medicines, over-the-counter drugs, vitamins, and herbal products to their treating clinician before starting Gleevec.

Food and Lifestyle Interactions

• Imatinib can be taken with or without food; a high-fat meal may modestly increase absorption, but consistency is more important than timing.
• Alcohol does not have a direct interaction but excessive intake can exacerbate liver toxicity.
• No specific restrictions on driving or operating machinery, but severe fatigue or dizziness warrants caution.

Dosing and Administration Guidelines

• Standard adult dose: 400 mg taken once daily as a single pill. This aligns with the most common approved regimens for CML and GIST.
• Dose reduction: For patients who cannot tolerate 400 mg, a 100 mg tablet may be added to achieve a total of 300 mg, or the dose may be reduced to 100 mg increments, guided by the prescribing oncologist.
• Special adjustments: Renal or hepatic impairment may necessitate a lower dose; the exact amount should be individualized by the treating physician.
• Administration: Swallow the pill whole with water. Do not crush, chew, or split the tablet unless instructed by a pharmacist.
• Missed dose: Take the missed dose as soon as remembered on the same day; do not take a double dose to “make up” for the missed one.
• Overdose: Symptoms may include severe nausea, vomiting, diarrhea, and dizziness. Seek emergency medical care; activated charcoal may be administered if presentation is early.
• Discontinuation: Gleevec is not typically tapered; abrupt cessation may be appropriate under medical supervision for certain scenarios, such as surgery.

Monitoring and Follow-Up

Regular monitoring is essential to ensure safety and effectiveness:

• Baseline labs: Complete blood count (CBC), liver function tests (ALT, AST, bilirubin), and renal function (creatinine, eGFR).
• Ongoing labs: CBC and liver tests every 2-4 weeks for the first three months, then monthly or as clinically indicated.
• Molecular response monitoring: For CML, quantitative PCR testing for BCR-ABL transcripts is performed every 3 months to gauge disease control.
• Clinical assessment: Patients should report new or worsening symptoms promptly. Routine oncology follow-up visits are required to assess tumor response and adjust therapy.

Storage and Handling

• Store Gleevec tablets at room temperature (15 °C-30 °C), away from excess moisture and direct sunlight.
• Keep the medication in its original container with the lid tightly closed.
• Do not use the product after the expiration date printed on the package.
• For safe disposal, return unused tablets to a pharmacy or follow local hazardous waste guidelines; do not flush or throw them in household trash.

Medication-Specific Glossary

Tyrosine-Kinase Inhibitor (TKI)

A class of drugs that block enzymes (tyrosine kinases) involved in signaling pathways that promote cancer cell growth.

BCR-ABL Fusion Protein

An abnormal enzyme produced by a chromosome translocation (Philadelphia chromosome) that drives chronic myeloid leukemia. Imatinib specifically inhibits this protein.

c-KIT Receptor

A cell-surface receptor commonly mutated in gastrointestinal stromal tumors; inhibition by imatinib slows tumor proliferation.

CYP3A4

A liver enzyme responsible for metabolizing many drugs, including imatinib. Substances that affect CYP3A4 can alter imatinib levels.

Hematologic Toxicity

Damage to blood-forming cells, leading to low counts of neutrophils, red cells, or platelets.

Medical Disclaimer

This article provides educational information about Gleevec and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.